Announcements
- Avalo Reports First Quarter 2024 Financial Results and Provides Business Updates
- Avalo Therapeutics Appoints Biotech Leaders to Board of Directors
- Avalo Reports 2023 Financial Results and Provides Business Updates
- Avalo Acquires Anti-IL-1β mAb and Announces Private Placement Financing of up to $185 Million
- Avalo Therapeutics Announces 1-for-240 Reverse Stock Split
- Avalo Encourages Stockholders to Vote FOR the Reverse Stock Split
- Avalo Reports Third Quarter 2023 Financial Results and Provides Business Updates
- Avalo Completes Divestiture of AVTX-800 Series
- Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
- Avalo Enters into Agreement to Divest AVTX-800 Series
More ▼
Key statistics
On Thursday, Avalo Therapeutics Inc (C6K0:FRA) closed at 9.78, 3,975.00% above the 52 week low of 0.24 set on Nov 13, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.78 |
---|---|
High | 9.78 |
Low | 9.78 |
Bid | 9.90 |
Offer | 10.60 |
Previous close | 9.86 |
Average volume | 25.56 |
---|---|
Shares outstanding | 1.03m |
Free float | 974.82k |
P/E (TTM) | -- |
Market cap | 11.16m USD |
EPS (TTM) | -318.69 USD |
Data delayed at least 15 minutes, as of May 23 2024 07:23 BST.
More ▼